Takebe et al. [103] determined that the recommended phase II dosage of adavosertib was once daily, and partial remission was observed in 14% of patients with advanced solid tumors (including two patients with endometrial cancer), with CCNE1 overexpression before treatment in two patients. Here, CCNE1 is linked to endometrial cancer.